RAISE Presentations at WSC 2021

RAISE Presentations at WSC 2021

Just before the World Stroke Congress 2021, a Roundtable of Academia & Industry for Stroke prEvention (RAISE) will be held in Arlington VA, USA, to facilitate collaboration between public and private sector experts. They will share their knowledge and achieve consensus on strategies intended to improve stroke prevention approaches through advances in research studies and clinical practice.

The RAISE conference will start with a 1-day invitation only meeting, featuring more than 20 different presentations. These presentations will cover cutting-edge research study designs, analytic methods, novel drugs/devices, biomarkers, and outcomes.

WSC 2021 Participants will have free access to most of these presentations on-demand, inside the Virtual Congress platform!

Additionally, 2 RAISE Satellite Sessions will be held live during WSC 2021.

The following RAISE Satellite Sessions will be held during WSC 2021:

NEW FRONTIERS IN NEUROCARDIOLOGY IN 2020s

Chair: M. Edip Gurol (Neurology, MGH/HMS)

THE ROLE OF THE NEUROLOGIST IN THE MANAGEMENT OF NEUROCARDIOLOGIC CONDITIONS

M. Edip Gurol (Neurology, MGH/HMS)

ADVANCES IN ATRIAL FIBRILLATION DETECTION

Nicole Sur (Neurology, Univ. Miami)

LEFT ATRIAL APPENDAGE CLOSURE: FROM RCTS TO WORLDWIDE IMPLEMENTATION

Speaker will be announced soon

PFOs: TO CLOSE OR NOT TO CLOSE

Luciano Sposato (Neurology, Western University, London, ON, CA)

HEATH CARE DELIVERY MODELS AND TRANSITIONS OF CARE

Chair: Anjail Sharrief (Neurology, Univ Texas Houston)

TRANSITIONS OF CARE AFTER STROKE: WHO, WHERE, AND WHEN?

Cheryl Bushnell (Neurology, Wake Forest)

COMMUNITY-BASED INTERVENTIONS FOR MANAGEMENT OF STROKE RISK FACTORS

Amy Towfighi (Neurology, USC/LAC)

POST-STROKE CARE IN SUBSAHARAN AFRICA. UTILIZATION OF MHEALTH AND IMPLICATIONS FOR OPTIMIZATION OF CARE DELIVERY IN UNDER-RESOURCED POPULATIONS

Bruce Ovbiagele (Neurology, UCSF/SFVAHCS)

THE IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON TRANSITIONS OF CARE AND POST-STROKE CARE

Anjail Sharrief (Neurology, Univ Texas Houston)

RAISE Presentations which will be available on demand at WSC 2021:

NEUROIMAGING AND OTHER BIOMARKERS RELEVANT TO PREVENTION OF STROKE

Co-Chairs: Jin-Moo Lee (Neurology, Wash U. St-Louis), Jose G. Merino (Neurology, Georgetown U, DC)

UNDERSTANDING INTRACEREBRAL HEMORRHAGE RISK AND ITS RELEVANCE IN STROKE PREVENTION

Alvin S. Das (Neurology, MGH/HMS)

PLASMA BIOMARKERS OF STROKE RISK AND ETIOLOGY

Hooman Kamel (Neurology, Cornell)

COGNITION AS AN OUTCOME MEASURE IN STROKE PREVENTION TRIALS

Rebecca Gottesman (NINDS)

HOW TO INCORPORATE IMAGING MARKERS IN STROKE PREVENTION TRIALS

Jonathan Graff-Radford (Neurology, Mayo Clinic Rochester)

NOVEL TREATMENT TARGETS IN CEREBRAL SMALL VESSEL DISEASES

Steven M. Greenberg (Neurology, MGH/HMS)

PREVENTION OF ISCHEMIC AND HEMORRHAGIC STROKES IN ATRIAL FIBRILLATION

Co-Chairs: Jennifer Majersik (Neurology, Univ. Utah), Christine M. Albert (Cardiac EP, Cedars Sinai)

AFIB DETECTION AND THE RELEVANCE OF AFIB LOAD

Lee H. Schwamm (Neurology, MGH/HMS)

LEFT ATRIAL APPENDAGE: ANATOMY, FUNCTION AND ITS ROLE IN AFIB-RELATED EMBOLISM

Shadi Yaghi (Neurology, NYU Neurology)

LEFT ATRIAL APPENDAGE CLOSURE FOR STROKE PREVENTION IN AFIB

Vivek Reddy (Cardiac EP, Mount Sinai, NYC)

EMERGING APPROACHES: AFIB ABLATION, CARDIAC IMAGING

Moussa Mansour (Cardiology, MGH/HMS)

IMPACT OF ATRIAL FIBRILLATION GENETICS ON DETECTION AND STROKE PREVENTION

Bradford Worrall (Neurology, Univ. Virginia)

OTHER ETIOLOGIES OF STROKES: MECHANISMS AND EMERGING TREATMENTS

Co-Chairs: Bruce Ovbiagele (Neurology, UCSF/SFVAHCS), Joseph Broderick (Neurology, Univ. Cincinnati)

PFOS AND THEIR CLOSURE: WHAT OTHER DATA ARE NEEDED?

Jeff Saver (Neurology, UCLA)

SURGICAL MEASURES FOR STROKE PREVENTION: FROM LAA CLIPPING TO PROTECTIVE DEVICES

Christopher R. Ellis (Cardiology, U. Vanderbuilt)

ADVANCES IN PLATELET AGGREGATION INHIBITORS FOR STROKE PREVENTION

Gregory W. Albers (Neurology, Stanford Univ.)

UPDATES ON LARGE VESSEL DISEASE TREATMENT: CREST-2 AND BEYOND

James Meschia (Neurology, Mayo Clinic, Jacksonville)

RUNNING PRAGMATIC TRIALS & IMPLEMENTATION STUDIES IN AHA’S GWTG

Jonathan Piccini (Cardiac EP, Duke)

EMERGING ISSUES IN RISK FACTOR MANAGEMENT

Co-Chairs: Louise McCullough (Neurology, Univ Texas Houston), Kevin Sheth (Neurology, Yale)

SEX AND RACE DIFFERENCES IN STROKE PREVENTION: ISSUES RELEVANT TO CLINICAL TRIALS AND PRACTICE

Anjail Sharrief (Neurology, Univ Texas Houston)

NOACS BEYOND NVAF AND DVT: WHAT HAVE WE LEARNED FROM COMPASS & ESUS STUDIES

Ralph Sacco (Neurology, Univ Miami)

FACTOR XI INHIBITORS

C. Michael Gibson (Cardiology, BIDMC, Boston, MA)

PCSK9 INHIBITORS FOR STROKE PREVENTION: CURRENT STATUS AND FUTURE DIRECTIONS

HOW TO DESIGN A TRIAL TO ACHIEVE FDA APPROVAL FOR A NEW INDICATION

Andrew Farb (FDA)